Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 28 | 2024 | 1769 | 1.540 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 9 | 2024 | 121 | 1.340 |
Why?
|
Androgen Antagonists | 8 | 2024 | 154 | 0.670 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 2567 | 0.580 |
Why?
|
Receptors, Androgen | 2 | 2017 | 123 | 0.550 |
Why?
|
PTEN Phosphohydrolase | 1 | 2016 | 136 | 0.510 |
Why?
|
Fatigue | 5 | 2011 | 179 | 0.410 |
Why?
|
Bone Neoplasms | 4 | 2019 | 329 | 0.380 |
Why?
|
Prostate-Specific Antigen | 8 | 2024 | 360 | 0.330 |
Why?
|
Neoplasms, Hormone-Dependent | 2 | 2018 | 41 | 0.300 |
Why?
|
Male | 46 | 2024 | 42423 | 0.290 |
Why?
|
Hypercalcemia | 10 | 1990 | 62 | 0.280 |
Why?
|
Androstenes | 2 | 2024 | 45 | 0.270 |
Why?
|
Antineoplastic Agents | 7 | 2019 | 2415 | 0.270 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 77 | 0.270 |
Why?
|
Quality of Life | 9 | 2022 | 1668 | 0.250 |
Why?
|
Testosterone | 4 | 2024 | 276 | 0.250 |
Why?
|
Phthalazines | 1 | 2024 | 45 | 0.240 |
Why?
|
5-alpha Reductase Inhibitors | 2 | 2014 | 12 | 0.230 |
Why?
|
Taxoids | 3 | 2015 | 130 | 0.230 |
Why?
|
Aged, 80 and over | 15 | 2024 | 6815 | 0.230 |
Why?
|
Neoplasm Metastasis | 11 | 2024 | 1110 | 0.220 |
Why?
|
Thrombin | 1 | 2003 | 61 | 0.210 |
Why?
|
Aged | 24 | 2024 | 19175 | 0.210 |
Why?
|
Surveys and Questionnaires | 6 | 2013 | 2630 | 0.210 |
Why?
|
Piperazines | 1 | 2024 | 283 | 0.210 |
Why?
|
Prednisone | 4 | 2024 | 259 | 0.200 |
Why?
|
Ataxia Telangiectasia Mutated Proteins | 2 | 2024 | 55 | 0.200 |
Why?
|
Mice, Nude | 16 | 2014 | 815 | 0.190 |
Why?
|
Humans | 52 | 2024 | 89367 | 0.190 |
Why?
|
BRCA2 Protein | 2 | 2024 | 161 | 0.180 |
Why?
|
Lung Neoplasms | 15 | 2003 | 2364 | 0.180 |
Why?
|
Carcinoma, Squamous Cell | 11 | 2003 | 1097 | 0.180 |
Why?
|
Metformin | 1 | 2022 | 124 | 0.180 |
Why?
|
BRCA1 Protein | 2 | 2024 | 204 | 0.180 |
Why?
|
DNA Repair | 2 | 2024 | 362 | 0.180 |
Why?
|
Middle Aged | 24 | 2024 | 25989 | 0.180 |
Why?
|
Radium | 1 | 2019 | 7 | 0.170 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2023 | 401 | 0.160 |
Why?
|
Etidronic Acid | 2 | 1991 | 5 | 0.160 |
Why?
|
Kallikreins | 1 | 2017 | 49 | 0.150 |
Why?
|
Carcinoma, Renal Cell | 2 | 1994 | 437 | 0.150 |
Why?
|
Cost of Illness | 1 | 2018 | 147 | 0.140 |
Why?
|
Neoplasms | 4 | 2007 | 3041 | 0.140 |
Why?
|
Pain | 3 | 2010 | 399 | 0.140 |
Why?
|
Finasteride | 3 | 2013 | 8 | 0.140 |
Why?
|
Orchiectomy | 3 | 2011 | 72 | 0.130 |
Why?
|
Kidney Neoplasms | 2 | 1994 | 638 | 0.130 |
Why?
|
Urination Disorders | 2 | 2013 | 50 | 0.130 |
Why?
|
Biomarkers, Tumor | 3 | 2024 | 1552 | 0.130 |
Why?
|
Decorin | 1 | 2014 | 6 | 0.120 |
Why?
|
Oncolytic Viruses | 1 | 2014 | 24 | 0.120 |
Why?
|
Calcium | 9 | 2008 | 1175 | 0.120 |
Why?
|
Neoplasm Transplantation | 11 | 2014 | 397 | 0.120 |
Why?
|
Oncolytic Virotherapy | 1 | 2014 | 42 | 0.120 |
Why?
|
Echinomycin | 1 | 1994 | 2 | 0.120 |
Why?
|
Thioguanine | 1 | 1994 | 17 | 0.120 |
Why?
|
Steroid 17-alpha-Hydroxylase | 1 | 2014 | 18 | 0.120 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2000 | 244 | 0.110 |
Why?
|
Germ-Line Mutation | 1 | 2016 | 344 | 0.110 |
Why?
|
Androgens | 4 | 2024 | 176 | 0.110 |
Why?
|
Naphthalenes | 1 | 2014 | 45 | 0.110 |
Why?
|
Urinary Bladder Neck Obstruction | 1 | 2013 | 21 | 0.110 |
Why?
|
Imidazoles | 1 | 2014 | 148 | 0.110 |
Why?
|
Tumor Suppressor Proteins | 2 | 2015 | 290 | 0.110 |
Why?
|
Prostate | 1 | 2016 | 393 | 0.100 |
Why?
|
Pharmacogenetics | 1 | 2016 | 443 | 0.100 |
Why?
|
Prothrombin | 2 | 2003 | 17 | 0.100 |
Why?
|
Adenocarcinoma | 3 | 2015 | 1195 | 0.100 |
Why?
|
Cell Line, Tumor | 3 | 2014 | 2558 | 0.090 |
Why?
|
Cholestenone 5 alpha-Reductase | 1 | 2010 | 2 | 0.090 |
Why?
|
Blood Coagulation | 2 | 2003 | 92 | 0.090 |
Why?
|
Urinary Incontinence | 1 | 2013 | 213 | 0.090 |
Why?
|
Genomics | 1 | 2016 | 762 | 0.090 |
Why?
|
Enzyme Inhibitors | 2 | 2010 | 645 | 0.090 |
Why?
|
Mitoxantrone | 1 | 2010 | 68 | 0.090 |
Why?
|
Peptide Fragments | 3 | 2003 | 463 | 0.090 |
Why?
|
Survival Rate | 5 | 2015 | 1903 | 0.090 |
Why?
|
Arabinonucleotides | 1 | 1989 | 3 | 0.090 |
Why?
|
Mice | 17 | 2014 | 11764 | 0.090 |
Why?
|
Vidarabine Phosphate | 1 | 1989 | 5 | 0.090 |
Why?
|
Hormones | 3 | 2022 | 139 | 0.080 |
Why?
|
Sulfonamides | 1 | 2011 | 318 | 0.080 |
Why?
|
Cisplatin | 4 | 2000 | 618 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2010 | 157 | 0.080 |
Why?
|
Pyrimidines | 1 | 2011 | 374 | 0.080 |
Why?
|
Ergocalciferols | 1 | 2008 | 38 | 0.080 |
Why?
|
Cell Cycle | 1 | 2010 | 509 | 0.080 |
Why?
|
Treatment Outcome | 7 | 2018 | 8245 | 0.070 |
Why?
|
Anorexia | 1 | 2007 | 30 | 0.070 |
Why?
|
Nitriles | 2 | 2022 | 160 | 0.070 |
Why?
|
Trans-Activators | 1 | 2010 | 443 | 0.070 |
Why?
|
Psychometrics | 2 | 2010 | 330 | 0.070 |
Why?
|
Epidermal Growth Factor | 1 | 1987 | 117 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2023 | 838 | 0.070 |
Why?
|
Neoplasm Staging | 4 | 2014 | 2018 | 0.070 |
Why?
|
Adult | 11 | 2017 | 26625 | 0.070 |
Why?
|
Thiadiazoles | 1 | 1986 | 12 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2010 | 618 | 0.070 |
Why?
|
Animals | 18 | 2014 | 27380 | 0.070 |
Why?
|
Nuclear Proteins | 1 | 2010 | 726 | 0.070 |
Why?
|
Disease Models, Animal | 6 | 2014 | 2367 | 0.070 |
Why?
|
Fluorouracil | 2 | 2000 | 561 | 0.060 |
Why?
|
Plicamycin | 1 | 1985 | 9 | 0.060 |
Why?
|
Factor Analysis, Statistical | 1 | 2005 | 114 | 0.060 |
Why?
|
Stress, Psychological | 1 | 2007 | 322 | 0.060 |
Why?
|
Carcinoma, Small Cell | 1 | 1985 | 133 | 0.060 |
Why?
|
Abiraterone Acetate | 1 | 2024 | 12 | 0.060 |
Why?
|
Castration | 1 | 2024 | 41 | 0.060 |
Why?
|
Time Factors | 5 | 2018 | 5339 | 0.060 |
Why?
|
Administration, Intravesical | 1 | 2023 | 34 | 0.060 |
Why?
|
BCG Vaccine | 1 | 2023 | 35 | 0.050 |
Why?
|
Vinblastine | 1 | 2003 | 108 | 0.050 |
Why?
|
Health Surveys | 1 | 2003 | 240 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2023 | 175 | 0.050 |
Why?
|
Registries | 2 | 2018 | 786 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2003 | 1121 | 0.050 |
Why?
|
Androgen Receptor Antagonists | 1 | 2022 | 22 | 0.050 |
Why?
|
Dutasteride | 2 | 2013 | 5 | 0.050 |
Why?
|
Azasteroids | 2 | 2013 | 5 | 0.050 |
Why?
|
Mice, Inbred BALB C | 4 | 2014 | 1088 | 0.050 |
Why?
|
Mifepristone | 1 | 2022 | 34 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2010 | 2759 | 0.050 |
Why?
|
Amino Acids | 1 | 2003 | 245 | 0.050 |
Why?
|
Phenylthiohydantoin | 1 | 2022 | 48 | 0.050 |
Why?
|
Interleukin-6 | 1 | 2003 | 261 | 0.050 |
Why?
|
Parathyroid Hormone | 4 | 1990 | 217 | 0.050 |
Why?
|
Benzamides | 1 | 2022 | 238 | 0.050 |
Why?
|
Receptors, Glucocorticoid | 1 | 2022 | 131 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2003 | 424 | 0.050 |
Why?
|
Dihydrotestosterone | 2 | 2010 | 28 | 0.050 |
Why?
|
Survival Analysis | 2 | 2016 | 1534 | 0.040 |
Why?
|
Etoposide | 1 | 2000 | 206 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 887 | 0.040 |
Why?
|
Injections, Subcutaneous | 2 | 1991 | 125 | 0.040 |
Why?
|
Carboplatin | 2 | 2015 | 312 | 0.040 |
Why?
|
Drug Evaluation | 3 | 1989 | 138 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2015 | 784 | 0.040 |
Why?
|
United States | 3 | 2018 | 6997 | 0.040 |
Why?
|
Body Mass Index | 1 | 2022 | 773 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2000 | 277 | 0.040 |
Why?
|
Female | 9 | 2007 | 46222 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2017 | 25 | 0.040 |
Why?
|
Public Health Surveillance | 1 | 2018 | 21 | 0.040 |
Why?
|
Bone and Bones | 2 | 1990 | 269 | 0.040 |
Why?
|
Antibodies | 2 | 1990 | 353 | 0.040 |
Why?
|
Interviews as Topic | 2 | 2010 | 339 | 0.040 |
Why?
|
Benzimidazoles | 1 | 2017 | 111 | 0.040 |
Why?
|
Cell Line | 3 | 1991 | 2496 | 0.030 |
Why?
|
Biomarkers | 1 | 2003 | 1767 | 0.030 |
Why?
|
Physicians | 1 | 2003 | 690 | 0.030 |
Why?
|
Diarrhea | 2 | 2011 | 182 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2016 | 142 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2016 | 280 | 0.030 |
Why?
|
Everolimus | 1 | 2015 | 40 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 286 | 0.030 |
Why?
|
Disease Progression | 2 | 2015 | 1489 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 588 | 0.030 |
Why?
|
Research | 1 | 2016 | 252 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2016 | 374 | 0.030 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2015 | 72 | 0.030 |
Why?
|
Bone Resorption | 3 | 1990 | 42 | 0.030 |
Why?
|
Neutropenia | 1 | 2015 | 216 | 0.030 |
Why?
|
Caregivers | 1 | 2016 | 160 | 0.030 |
Why?
|
Prospective Studies | 2 | 2022 | 4293 | 0.030 |
Why?
|
Transplantation, Heterologous | 3 | 2010 | 370 | 0.030 |
Why?
|
Health Care Costs | 1 | 2016 | 235 | 0.030 |
Why?
|
Heterografts | 1 | 2014 | 102 | 0.030 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 852 | 0.030 |
Why?
|
Gene Transfer Techniques | 1 | 2014 | 153 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2015 | 187 | 0.030 |
Why?
|
Comorbidity | 1 | 2018 | 949 | 0.030 |
Why?
|
Disease Management | 1 | 2016 | 329 | 0.030 |
Why?
|
Databases, Factual | 1 | 2017 | 856 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2015 | 340 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 260 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 1994 | 240 | 0.030 |
Why?
|
Climacteric | 1 | 1993 | 4 | 0.030 |
Why?
|
Kidney | 2 | 1989 | 1147 | 0.030 |
Why?
|
Goserelin | 1 | 1993 | 6 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2016 | 866 | 0.030 |
Why?
|
Retrospective Studies | 2 | 2017 | 9058 | 0.030 |
Why?
|
Osteoclasts | 2 | 1990 | 35 | 0.030 |
Why?
|
Drug Resistance | 1 | 1994 | 232 | 0.030 |
Why?
|
Leuprolide | 1 | 1993 | 35 | 0.030 |
Why?
|
Clonidine | 1 | 1993 | 33 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2016 | 460 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 1 | 2015 | 860 | 0.030 |
Why?
|
Mutation | 1 | 2024 | 4143 | 0.030 |
Why?
|
Phosphorylation | 1 | 2015 | 1132 | 0.030 |
Why?
|
Symptom Assessment | 1 | 2013 | 66 | 0.030 |
Why?
|
Follow-Up Studies | 2 | 2015 | 3667 | 0.030 |
Why?
|
Mice, SCID | 1 | 2013 | 261 | 0.030 |
Why?
|
Triazoles | 1 | 2013 | 102 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2016 | 1862 | 0.030 |
Why?
|
United States Department of Defense | 1 | 2011 | 5 | 0.030 |
Why?
|
Age Factors | 1 | 2016 | 1871 | 0.020 |
Why?
|
Early Termination of Clinical Trials | 1 | 2011 | 16 | 0.020 |
Why?
|
Urology | 1 | 2013 | 117 | 0.020 |
Why?
|
Indazoles | 1 | 2011 | 67 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2003 | 1942 | 0.020 |
Why?
|
Tumor Cells, Cultured | 2 | 1993 | 1057 | 0.020 |
Why?
|
Cell Movement | 1 | 2014 | 784 | 0.020 |
Why?
|
Universities | 1 | 2011 | 148 | 0.020 |
Why?
|
Tissue Extracts | 1 | 1990 | 24 | 0.020 |
Why?
|
Patient Compliance | 1 | 2011 | 231 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2010 | 225 | 0.020 |
Why?
|
Health Status Indicators | 1 | 2010 | 103 | 0.020 |
Why?
|
Self Concept | 1 | 2010 | 133 | 0.020 |
Why?
|
Area Under Curve | 1 | 2010 | 337 | 0.020 |
Why?
|
25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 1989 | 10 | 0.020 |
Why?
|
Steroid Hydroxylases | 1 | 1989 | 14 | 0.020 |
Why?
|
Cell Division | 1 | 2010 | 696 | 0.020 |
Why?
|
Estradiol | 1 | 2010 | 251 | 0.020 |
Why?
|
Medical Oncology | 1 | 2013 | 383 | 0.020 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 1989 | 78 | 0.020 |
Why?
|
Prognosis | 1 | 2016 | 3787 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2013 | 1800 | 0.020 |
Why?
|
Weight Loss | 1 | 2010 | 227 | 0.020 |
Why?
|
Data Collection | 1 | 2010 | 375 | 0.020 |
Why?
|
Pain Measurement | 1 | 2010 | 328 | 0.020 |
Why?
|
Oncogenes | 1 | 1988 | 92 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2010 | 470 | 0.020 |
Why?
|
Gene Amplification | 1 | 1988 | 134 | 0.020 |
Why?
|
Laryngeal Neoplasms | 1 | 1988 | 89 | 0.020 |
Why?
|
Calcitriol | 1 | 1989 | 173 | 0.020 |
Why?
|
Anxiety | 1 | 2010 | 308 | 0.020 |
Why?
|
Carnitine | 1 | 1987 | 14 | 0.020 |
Why?
|
Thymectomy | 1 | 1987 | 31 | 0.020 |
Why?
|
Risk Factors | 1 | 2018 | 5497 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2013 | 1653 | 0.020 |
Why?
|
Chicago | 1 | 2011 | 1427 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2007 | 187 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 299 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 1988 | 540 | 0.020 |
Why?
|
ROC Curve | 1 | 2007 | 780 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2010 | 1266 | 0.020 |
Why?
|
Proteins | 1 | 1990 | 787 | 0.020 |
Why?
|
Doxorubicin | 1 | 1985 | 301 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2008 | 1719 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2007 | 1072 | 0.010 |
Why?
|
Safety | 1 | 2003 | 149 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2003 | 272 | 0.010 |
Why?
|
Hematologic Diseases | 1 | 2000 | 78 | 0.010 |
Why?
|
Parathyroid Hormone-Related Protein | 2 | 1990 | 12 | 0.010 |
Why?
|
Cause of Death | 1 | 2000 | 269 | 0.010 |
Why?
|
Immunoassay | 1 | 1999 | 91 | 0.010 |
Why?
|
Microscopy, Electron | 2 | 1990 | 511 | 0.010 |
Why?
|
Remission Induction | 1 | 2000 | 740 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 1985 | 1063 | 0.010 |
Why?
|
Pilot Projects | 1 | 2000 | 871 | 0.010 |
Why?
|
Reference Values | 2 | 1989 | 661 | 0.010 |
Why?
|
Phosphorus | 2 | 1989 | 117 | 0.010 |
Why?
|
Venous Thrombosis | 1 | 1999 | 252 | 0.010 |
Why?
|
Adolescent | 1 | 2007 | 9267 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2000 | 1365 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 1993 | 435 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 1999 | 742 | 0.010 |
Why?
|
Pregnancy | 1 | 1999 | 3018 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 1993 | 576 | 0.010 |
Why?
|
Osteoblasts | 1 | 1990 | 98 | 0.010 |
Why?
|
Teriparatide | 1 | 1988 | 3 | 0.000 |
Why?
|
Osteocytes | 1 | 1988 | 9 | 0.000 |
Why?
|
Cattle | 1 | 1988 | 376 | 0.000 |
Why?
|
Cyclic AMP | 1 | 1988 | 274 | 0.000 |
Why?
|
Minerals | 1 | 1984 | 22 | 0.000 |
Why?
|
Magnesium | 1 | 1984 | 178 | 0.000 |
Why?
|
Spine | 1 | 1984 | 102 | 0.000 |
Why?
|